Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance

被引:0
|
作者
Doherty, J. [1 ]
Varley, R. [1 ]
Healy, M. [2 ]
Dunne, C. [1 ]
Mac Carthy, F. [1 ]
McKiernan, S. [1 ]
Hartery, K. [1 ]
Kevans, D. [1 ]
机构
[1] St James Hosp, Dept Gastroenterol, Dublin 8, Ireland
[2] St James Hosp, Dept Biochem, Dublin 8, Ireland
来源
关键词
D O I
10.1093/ecco-jcc/jjab076.532
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P408
引用
收藏
页码:S415 / S416
页数:3
相关论文
共 50 条
  • [1] ANTI-DRUG ANTIBODIES DETECTED IN THE PRESENCE OF ADEQUATE INFLIXIMAB DRUG LEVELS IN IBD PATIENTS IN CLINICAL REMISSION HAVE LIMITED CLINICAL SIGNIFICANCE
    Doherty, Jayne
    Varley, Rachel
    Healy, Martin
    Dunne, Cara
    Maccarthy, Finbar
    Mckiernan, Susan
    Hartery, Karen
    Kevans, David
    GASTROENTEROLOGY, 2021, 160 (06) : S692 - S692
  • [2] Clinical Outcome of Pediatric IBD Patients After Measurement of Infliximab Drug and Anti-Drug Antibody Levels
    Turon, Joanna
    Langseder, Annette
    Irizarry, Ruth
    Ahuja, Komal
    Rosh, Joel R.
    GASTROENTEROLOGY, 2013, 144 (05) : S531 - S531
  • [3] UTILITY OF MEASURING INFLIXIMAB DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN CLINICAL PRACTICE: A LARGE IBD REFERRAL CENTRE EXPERIENCE
    Johnston, E. L.
    Warner, B. D.
    Digby-Bell, J. L.
    Unsworth, N.
    Anderson, S.
    Sanderson, J. D.
    Arkir, Z.
    Irving, P. M.
    GUT, 2015, 64 : A227 - A228
  • [4] The temporal evolution of anti-drug antibodies in IBD patients treated with infliximab
    Ben-Horin, Shomron
    Ungar, Bella
    Chowers, Yehuda
    Yavzori, Miri
    Picard, Orit
    Fudim, Ella
    Eliakim, Rami
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 145 - 145
  • [5] Clinical utility of vedolizumab trough levels and anti-drug antibodies in the management of IBD
    Jelk, D.
    Perreau, M.
    Michetti, P.
    Maillard, M.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S410 - S410
  • [6] INFLIXIMAB TROUGH LEVELS AND ANTI-DRUG ANTIBODIES AFTER INDUCTION AS PREDICTIVE FACTORS OF LONG TERM CLINICAL REMISSION
    Bodini, G.
    Del Nero, L.
    Giannini, E.
    De Maria, C.
    Baldissarro, I
    Savarino, V
    Savarino, E.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E163 - E163
  • [7] INCIDENCE AND CLINICAL OUTCOME OF ANTI-DRUG ANTIBODIES IN INFLIXIMAB-TREATED PATIENTS
    Bartoli, F.
    Fiori, G.
    Galluccio, F.
    Petroni, G.
    Pratesi, S.
    Matucci, A.
    Vultaggio, A.
    Nacci, F.
    Nencini, F.
    Maggi, E.
    Matucci-Cerinic, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 514 - 514
  • [8] Evaluation of Immunoassays for the Detection of Anti-Drug Antibodies Against Infliximab and the Corresponding Drug Levels in Patients with Spondyloarthritis in Clinical Practice
    Von Bremen, Helene
    Gamboa, Lorena Martinez
    Zernicke, Jan
    Poddubnyy, Denis
    Feist, Eugen
    AKTUELLE RHEUMATOLOGIE, 2021, 46 (05) : 465 - 473
  • [9] Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis
    Siljehult, F.
    Arlestig, L.
    Eriksson, C.
    Rantapaa-Dahlqvist, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 (05) : 345 - 350
  • [10] The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
    Neasa Mc Gettigan
    Aman Shah Afridi
    Grace Harkin
    Caroline Lardner
    Stephen Patchett
    Danny Cheriyan
    Gavin Harewood
    Karen Boland
    Aoibhlinn O’Toole
    International Journal of Colorectal Disease, 2021, 36 : 1231 - 1241